NEURO
Unlock the brain.Keep the molecule.
Apertum primes the blood-brain barrier with non-invasive stimulation—so systemic therapeutics reach the CNS without being redesigned.
↓01 / No surgery02 / No microbubbles03 / No nanoparticles04 / Molecule unchanged
01 / The constraint
Biology can work.
Delivery can fail.
The blood-brain barrier protects the brain—and blocks most therapeutic molecules from reaching useful exposure.
Apertum treats permeability as a platform problem. The goal is to unlock existing and next-generation therapeutics without redesigning the asset around the barrier.
02 / The platform
The device is not
the product. Delivery is.
A clinical workflow built to fit around the therapeutic—not force the therapeutic to fit around the technology.
Prime
A 45-minute non-invasive stimulation session transiently increases BBB permeability.
Infuse
The device is removed and the existing therapeutic is administered through a standard systemic infusion.
Deliver
The temporary permeability window increases exposure inside the central nervous system.
Discharge
The workflow is ambulatory—with no sedation, shaving, implanted device or hospital stay.
03 / Preclinical signal
Across species.
Into deep structures.
Systemic AAV–ARSA administration with Apertum treatment produced region-specific enzyme activity increases versus a no-opening control in non-human primates.
Regional ARSA activity map · Macaca mulattaRelative ARSA activity / control
Substantia nigra646.1%
Caudate217.8%
Putamen207.9%
Thalamus195.0%
Temporal cortex144.0%
Frontal cortex129.8%
Evidence ladderRodent efficacy & reversibilityPorcine permeabilityNHP functional AAV–ARSA signal
Regional resultActivity increased across cortical, basal-ganglia and thalamic regions.Substantia nigra reached 646.1% of the no-opening control.
04 / Contact
Start a focused
conversation.
Tell us where you are approaching CNS delivery from. Your message will go directly to Adrien and the Apertum team.